<?xml version="1.0" encoding="UTF-8"?>
<p>In accordance to the Infectious Diseases Society of America Guidelines on the treatment and management of patients with COVID-19 infection, convalescent plasma is recommended in the framework of a clinical trial.
 <sup>
  <xref rid="R45" ref-type="bibr">45</xref>
 </sup> Similarly, the International Society of Blood Transfusion (ISBT) Working Party on Global Blood Safety has underlined that the clinical use of convalescent plasma should be performed as an experimental therapy, ideally in the context of an organized research trial.
</p>
